-
摘要:
背景 纤毛在气道防御机制中发挥着重要作用。由于观察技术和设备的限制,既往关于鼻用糖皮质激素对纤毛运动影响的研究主要是基于离体试验,尚无相关的在体动物研究。 目的 使用一种新的方法观察并比较鼻用糖皮质激素对在体与离体鼻黏膜纤毛运动的影响。 方法 60只大鼠随机分为在体观察组和离体观察组,每组又随机分为布地奈德、糠酸莫米松和丙酸氟替卡松3个亚组,各亚组均以磷酸盐缓冲液(phosphate buffered saline,PBS)作为对照,每个试验组和对照组各5只大鼠。在体观察组将大鼠麻醉后立即手术暴露鼻中隔黏膜;离体观察组将大鼠过量麻醉后断头处死,取其鼻中隔黏膜放置于培养基中。两组皆放置于新型数码显微系统下观察鼻黏膜表面的纤毛运动情况,计算并比较60 min内在体与离体观察组大鼠鼻黏膜表面滴加药物前后纤毛摆动频率(ciliary beat frequency,CBF)的差异。 结果 在体观察组大鼠鼻黏膜的CBF显著高于离体观察组[(9.83 ± 0.94) Hz vs (6.10 ± 0.91) Hz,P<0.001]。在体观察发现,布地奈德、糠酸莫米松和丙酸氟替卡松在60 min内对大鼠鼻黏膜CBF无显著影响;而离体观察条件下,与PBS对照组相比,布地奈德使CBF即刻下降,在60 min内组间各时间点的CBF差异均有统计学意义(P<0.05);糠酸莫米松使CBF持续下降,且加药5 min后各时间点的CBF差异均有统计学意义(P<0.05);丙酸氟替卡松使CBF波动下降,且在0 ~ 5 min和20 ~ 60 min内各时间点的CBF差异均有统计学意义(P<0.05)。 结论 布地奈德、糠酸莫米松和丙酸氟替卡松对在体鼻黏膜的纤毛运动无显著影响,对离体鼻黏膜的纤毛运动均产生了不同程度的抑制作用,这表明鼻用糖皮质激素无显著的纤毛毒性,具有良好的安全性;同时本研究所使用的在体评估系统弥补了离体观察与机体真实环境差异较大的不足,可用于客观评价鼻用药物的安全性和纤毛毒性。 Abstract:Background Cilia plays an important role in airway defense mechanisms. However, due to limitations in the research techniques and tools for observation, in vivo animal studies on the effects of intranasal corticosteroids on ciliary motion are scarce. Objective To observe and investigate the effects of intranasal corticosteroids on nasal ciliary motion in vivo and in vitro using a new method. Methods Sixty rats were randomly divided into in vivo observation group and in vitro observation group. Each group was randomly divided into three subgroups: budesonide group, mometasone furoate and fluticasone propionate, and phosphate buffered saline (PBS) was used as the control for the three subgroups. Rats in the in vivo observation group were anesthetized and their nasal septal mucosae were surgically exposed immediately; while rats in the in vitro observation group were over-anesthetized, severed and executed, and their nasal septal mucosae were taken and placed in the culture medium. The ciliary motion on the nasal mucosal surface was observed under the new digital microscope system. The differences in ciliary beat frequency (CBF) between the two groups were compared before and after drug addition to the nasal mucosal surface of rats within 60 min. Results The CBF of nasal mucosa of the rats in the in vivo observation group was significantly higher than that in the in vitro observation group ([9.83 ± 0.94] Hz vs [6.10 ± 0.91] Hz, P<0.001). Under in vivo condition, budesonide, mometasone furoate, and fluticasone propionate had no significant effect on CBF in rats' nasal mucosa within 60 min. Under in vitro condition, budesonide caused an immediate decrease in CBF, with statistically significant differences in CBF between the two groups at all time points within 60 min (P<0.05); mometasone furoate decreased CBF continuously, and the differences in CBF between the two groups at each time point after 5 min of addition were statistically significant (P<0.05); fluticasone propionate caused a fluctuating decrease in CBF, and the differences in CBF between two groups at all time points from 0 to 5 min and from 20 to 60 min were statistically significant (P<0.05). Conclusion Budesonide, mometasone furoate, and fluticasone propionate have no significant effect on ciliary motion in vivo, while they all produce varying degrees of inhibition of ciliary motion in vitro, indicating that intranasal corticosteroids have no significant ciliary toxicity, with good safety. Meanwhile, the in vivo evaluation system used in this study compensates for the great difference between in vitro observation and the real physiological environment, which can be used to objectively evaluate the safety and ciliary toxicity of nasal drugs. -
Key words:
- intranasal corticosteroids /
- ciliary beat frequency /
- nasal mucosa /
- rats /
- digital microscope system
-
图 3 糠酸莫米松和PBS对在体和离体鼻黏膜CBF的影响
A:糠酸莫米松对在体CBF的影响;B:糠酸莫米松对离体CBF的影响(n=5;aP<0.05,bP<0.01,vs PBS)
Figure 3. Effect of mometasone furoate and PBS on CBF of nasal mucosa in vivo and in vitro
A: Effect of mometasone furoate on CBF in vivo; B: Effect of mometasone furoate on CBF in vitro (n=5; aP<0.05, bP<0.01, vs PBS)
图 4 丙酸氟替卡松和PBS对在体和离体鼻黏膜CBF的影响
A:丙酸氟替卡松对在体CBF的影响;B:丙酸氟替卡松对离体CBF的影响(n=5;aP<0.05,bP<0.01,vs PBS)
Figure 4. Effect of fluticasone propionate and PBS on CBF of nasal mucosa in vivo and in vitro
A: Effect of fluticasone propionate on CBF in vivo; B: Effect of fluticasone propionate on CBF in vitro (n=5; aP<0.05, bP<0.01, vs PBS)
-
[1] Dykewicz MS,Wallace DV,Amrol DJ,et al. Rhinitis 2020:a practice parameter update[J]. J Allergy Clin Immunol,2020,146(4): 721-767. doi: 10.1016/j.jaci.2020.07.007 [2] Bachert C,Marple B,Schlosser RJ,et al. Adult chronic rhinosinusitis[J]. Nat Rev Dis Primers,2020,6(1): 86. doi: 10.1038/s41572-020-00218-1 [3] Zhang K,Li AR,Miglani A,et al. Effect of medical therapy in allergic rhinitis:a systematic review and meta-analysis[J]. Am J Rhinol Allergy,2022,36(2): 269-280. doi: 10.1177/19458924211041438 [4] Abdelhafeez M. Effectiveness of intranasal steroids on rhinitis symptoms,sleep quality,and quality of life in patients with perennial allergic rhinitis[J]. Eur Arch Otorhinolaryngol,2022,279(1): 249-256. doi: 10.1007/s00405-021-06818-1 [5] Donaldson AM,Choby G,Kim DH,et al. Intranasal corticosteroid therapy:systematic review and meta-analysis of reported safety and adverse effects in adults[J]. Otolaryngol Head Neck Surg,2020,163(6): 1097-1108. doi: 10.1177/0194599820931455 [6] Jiao J,Meng N,Zhang L. The effect of topical corticosteroids,topical antihistamines,and preservatives on human ciliary beat frequency[J]. ORL J Otorhinolaryngol Relat Spec,2014,76(3): 127-136. doi: 10.1159/000363575 [7] Jiao J,Zhang L. Influence of intranasal drugs on human nasal mucociliary clearance and ciliary beat frequency[J]. Allergy Asthma Immunol Res,2019,11(3): 306-319. doi: 10.4168/aair.2019.11.3.306 [8] Bustamante-Marin XM,Ostrowski LE. Cilia and mucociliary clearance[J]. Cold Spring Harb Perspect Biol,2017,9(4): a028241. doi: 10.1101/cshperspect.a028241 [9] Tratnjek L,Kreft M,Kristan K,et al. Ciliary beat frequency of in vitro human nasal epithelium measured with the simple high-speed microscopy is applicable for safety studies of nasal drug formulations[J]. Toxicol In Vitro,2020,66: 104865. doi: 10.1016/j.tiv.2020.104865 [10] Allan KM, Wong SL, Fawcett LK, et al. Collection, expansion, and differentiation of primary human nasal epithelial cell models for quantification of Cilia beat frequency[J/OL].https://doi.org/10.3791/63090. [11] Carey RM,Adappa ND,Palmer JN,et al. Neuropeptide Y reduces nasal epithelial T2R bitter taste receptor-stimulated nitric oxide production[J]. Nutrients,2021,13(10): 3392. doi: 10.3390/nu13103392 [12] Legebeke J,Horton KL,Jackson CL,et al. Temporal whole-transcriptomic analysis of characterized in vitro and Ex vivo primary nasal epithelia[J]. Front Cell Dev Biol,2022,10: 907511. doi: 10.3389/fcell.2022.907511 [13] Pang C,An FW,Yang SM,et al. In vivo and in vitro observation of nasal ciliary motion in a Guinea pig model[J]. Exp Biol Med (Maywood),2020,245(12): 1039-1048. doi: 10.1177/1535370220926443 [14] Liu C,Pang C,Chen DS,et al. In vivo visualization and analysis of ciliary motion in allergic rhinitis models induced by ovalbumin[J]. Exp Biol Med (Maywood),2022,247(14): 1287-1297. doi: 10.1177/15353702221088781 [15] Francis R,Lo C. Ex vivo method for high resolution imaging of cilia motility in rodent airway epithelia[J]. J Vis Exp,2013,78: 50343. [16] Merkus P,Romeijn SG,Verhoef JC,et al. Classification of cilio-inhibiting effects of nasal drugs[J]. Laryngoscope,2001,111(4 Pt 1): 595-602. [17] Do BH,Ohbuchi T,Wakasugi T,et al. Acetylcholine-induced ciliary beat of the human nasal mucosa is regulated by the pannexin-1 channel and purinergic P2X receptor[J]. Am J Rhinol Allergy,2018,32(4): 217-227. doi: 10.1177/1945892418770292 [18] Liao YSJ,Kuan SP,Guevara MV,et al. Acid exposure disrupts mucus secretion and impairs mucociliary transport in neonatal piglet airways[J]. Am J Physiol Lung Cell Mol Physiol,2020,318(5): L873-L887. doi: 10.1152/ajplung.00025.2020 [19] Atar Y,Karaketir S,Aydogdu I,et al. Comparison of isotonic seawater nasal spray containing chamomile liquid extract and other isotonic seawater nasal washing solutions for allergic rhinitis[J]. Ann Otol Rhinol Laryngol,2022,131(4): 427-434. doi: 10.1177/00034894211025411 [20] 何刚,税磊. 丙酸氟替卡松对季节性过敏性鼻炎患者鼻腔生理功能的影响[J]. 医学综述,2017,23(12): 2486-2489. doi: 10.3969/j.issn.1006-2084.2017.12.042 [21] Naclerio RM,Baroody FM,Bidani N,et al. A comparison of nasal clearance after treatment of perennial allergic rhinitis with budesonide and mometasone[J]. Otolaryngol Head Neck Surg,2003,128(2): 220-227. doi: 10.1067/mhn.2003.70 [22] Thomas B,Rutman A,O'Callaghan C. Disrupted ciliated epithelium shows slower ciliary beat frequency and increased dyskinesia[J]. Eur Respir J,2009,34(2): 401-404. doi: 10.1183/09031936.00153308 [23] Chioccioli M,Feriani L,Kotar J,et al. Phenotyping ciliary dynamics and coordination in response to CFTR-modulators in Cystic Fibrosis respiratory epithelial cells[J]. Nat Commun,2019,10(1): 1763. doi: 10.1038/s41467-019-09798-3 [24] Shusterman D. A simplified technique for evaluating nasal mucociliary clearance via saccharin transit time[J]. Int Forum Allergy Rhinol,2020,10(4): 572-574. doi: 10.1002/alr.22528 [25] Laffleur F,Bauer B. Progress in nasal drug delivery systems[J]. Int J Pharm,2021,607: 120994. doi: 10.1016/j.ijpharm.2021.120994 [26] Keller LA,Merkel O,Popp A. Intranasal drug delivery:opportunities and toxicologic challenges during drug development[J]. Drug Deliv Transl Res,2022,12(4): 735-757. doi: 10.1007/s13346-020-00891-5 -